Other languages Bioxytran, Inc.

Equities

BIXT

US09075D1028

Market Closed - OTC Markets Other stock markets 03:39:08 2024-04-26 pm EDT			5-day change	1st Jan Change
0.12 ^USD	-11.11%		-9.43%	-20.00%

Apr. 19	Bioxytran, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 22	Bioxytran, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Bioxytran, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 19
Bioxytran, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 22
Bioxytran, Inc. Announces Preprint of Shingles Case Study Showing Clearance Using A Topical Galectin-3 Antagonist	Mar. 06
Bioxytran, Inc.'S Oral Antiviral Drug to Enter Dose Optimization Clinical Trial for Covid-19	Feb. 21
Bioxytran, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 03
Bioxytran, Inc. Receives Clearance of its Investigational New Drug Application from U.S. Food and Drug Administration to Initiate Clinical Trials of ProLectin-M	23-08-24
Bioxytran, Inc. Initiates A Registrational Trial of Oral ProLectin-M for Mild to Moderate COVID 19 Patients	23-08-08
Bioxytran, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-07-31
China metals export curbs lift shares in US producer MP Materials	23-07-05
China rare earth curbs lift shares in U.S. producer MP Materials	23-07-05
Bioxytran, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12
Bioxytran, Inc. Tests Acellular Oxygen Carrier BXT-25 in Pre-Clinical Trials	23-04-19
Bioxytran, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31
Bioxytran, Inc. Auditor Raises 'Going Concern' Doubt	23-03-30
Bioxytran, Inc. Announces Positive Phase 2 Trial Results	23-03-29
Bioxytran, Inc. Announces Vitro Testing At Foundation for Neglected Disease Research in Bangalore India	23-02-28
Bioxytran, Inc. Receives Approval to Initiate Trials with Prolectin-I	23-02-06
Bioxytran, Inc. Announces Crystal Research Update Highlights 100% Responders Rate in Mild to Moderate COVID-19 Trial	22-12-28
Bioxytran Establishes Indian Subsidiary Pharmalectin India Private Limited in Preparation of Commercialization	22-12-14
Bioxytran Receives Approval to Optimize Dosage in Covid-19 Patients	22-12-08

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Bioxytran, Inc.

Equities

BIXT

US09075D1028

Other languages

Filters